Tarsus Pharmaceuticals, Inc. TARS Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Option, Nonvested, Weighted Average Exercise Price at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price?
- Tarsus Pharmaceuticals, Inc. (TARS) reported share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price of $47.13 in Q1 2026.
- How has Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price increased by 56.3% year-over-year, from $30.16 to $47.13.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price has grown at a 50.9% compound annual growth rate (CAGR), from $4.41 to $34.46.
- What does share-based compensation arrangement by share-based payment award, option, nonvested, weighted average exercise price mean?
- This represents the average price at which non-vested share-based payment options may be exercised by employees. It serves as a benchmark for the cost basis of future equity issuance and reflects the company's historical valuation at the time of grant.